Semaglutide: an evidence-first deep dive

Already know this material? Pass the checkpoint and this lesson counts as complete.

Test out checkpoint

Test out: Semaglutide: an evidence-first deep dive

Already know the material? Pass this checkpoint without opening the lesson first.

Get every question correct to pass.

1. STEP 1 and SELECT should be interpreted as:

Two studies answering different clinical questions in different populationsDuplicate studies proving the same endpointMechanistic studies onlyEvidence that every GLP-1 medicine is identical

2. A strong semaglutide claim should name which context?

Population, product/formulation, comparator, outcome and durationOnly the peptide nameOnly the marketing categoryOnly the percentage change

3. If a trial shows a large average weight effect, does that prove every person will have the same result?

YesNo

4. What makes the SELECT endpoint especially informative?

It measured major cardiovascular events directlyIt only measured appetiteIt used a surrogate receptor assayIt was based on anecdotes

5. Which conclusion is too broad?

Semaglutide has large randomized human outcome evidenceA studied semaglutide product reduced weight in the STEP 1 populationEvery semaglutide-containing product has the same quality, device performance and evidenceProduct-specific context matters

PThe Pep Report

Educational information only. Not medical advice.

Personalised Guide Safety & info Research Sourcing Guide